Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does safety make a difference in selecting the right TNF antagonist?

Roy Fleischmann1, David Yocum

  • 1University of Texas Southwestern Medical Center, Dallas, TX, USA. royfleischmann@radiantresearch.com

Arthritis Research & Therapy
|July 2, 2004
PubMed
Summary

Tumor necrosis factor (TNF) antagonists improve rheumatoid arthritis outcomes. While generally well-tolerated with manageable side effects like injection site reactions and infections, ongoing research is needed for malignancy and demyelinating disorder risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study.

RMD open·2026
Same author

Response to correspondence on 'Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study' by Mysler et al.

Annals of the rheumatic diseases·2026
Same author

Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.

Annals of the rheumatic diseases·2026
Same author

Baseline Interleukin-10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease-Modifying Antirheumatic Drug Naive and Anti-Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis.

Rheumatology and therapy·2026
Same author

Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease.

RMD open·2025

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Biologic response modifiers, specifically Tumor Necrosis Factor (TNF) antagonists, have transformed rheumatoid arthritis (RA) treatment.
  • Established agents like infliximab and etanercept, alongside newer ones like adalimumab, offer significant clinical benefits.

Purpose of the Study:

  • To review the safety profiles of TNF antagonists used in rheumatoid arthritis treatment.
  • To consolidate safety data from extensive patient populations treated with infliximab, etanercept, and adalimumab.

Main Methods:

  • Compilation and analysis of safety data from post-marketing surveillance and clinical trials.
  • Review of adverse events, including injection-site reactions, infections, malignancies, and neurological disorders.

Related Experiment Videos

Main Results:

  • Infliximab, etanercept, and adalimumab demonstrate predictable and manageable safety profiles.
  • Common adverse events include injection-site/infusion reactions and infections, which are typically manageable.
  • Further investigation is required for potential risks such as malignancy and demyelinating disorders.

Conclusions:

  • TNF antagonists are well-tolerated in RA patients, offering a favorable benefit-to-risk ratio.
  • Proactive screening and monitoring can mitigate risks associated with infections.
  • Long-term studies are essential to fully elucidate the safety landscape of these biologic agents.